Press coverage about Anika Therapeutics (NASDAQ:ANIK) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.2855755363535 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Anika Therapeutics (NASDAQ ANIK) opened at 58.00 on Friday. The company has a 50-day moving average of $53.44 and a 200 day moving average of $47.83. Anika Therapeutics has a one year low of $41.38 and a one year high of $58.51. The firm has a market cap of $850.16 million, a PE ratio of 25.77 and a beta of 1.65.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.32. The firm had revenue of $33.50 million during the quarter, compared to analysts’ expectations of $27.20 million. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. Anika Therapeutics’s quarterly revenue was up 25.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.57 EPS. On average, equities research analysts expect that Anika Therapeutics will post $2.20 EPS for the current fiscal year.

ANIK has been the subject of several recent research reports. BidaskClub raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research raised shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 2nd.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Share Price” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at

In other news, CEO Charles H. Sherwood sold 63,799 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total transaction of $3,240,351.21. Following the completion of the transaction, the chief executive officer now directly owns 174,705 shares in the company, valued at approximately $8,873,266.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Charles H. Sherwood sold 14,201 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total value of $710,476.03. Following the transaction, the chief executive officer now owns 246,740 shares of the company’s stock, valued at $12,344,402.20. The disclosure for this sale can be found here. Corporate insiders own 6.57% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.